PHARMA STOCKS
Stock picks of the week: 5 stocks with consistent score improvement and return potential of more than 28% in 1 year
While the bulls were clearly making a comeback, the RBI’s move to cut both the repo rate and CRR has just helped them some more. Now, there are two schools of thought on the RBI move. One says a cut in interest rate suggests the economy is slowing and requires a push. The other says that boosting liquidity and giving cash in people’s hands, when done in time, aids a faster recovery. Whatever be the case, the one thing to keep an eye on is inflation. Our selected stocks for today depict a strong upward trajectory in their overall average score which is based on five key pillars: Earnings, fundamentals, relative valuation, risk, and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Stock market update: Stocks that hit 52-week lows on NSE in today's trade
HDFC Life, BEL, Bharti Airtel, Tata Steel and Sun Pharma were among the top losers on NSE in today's trade.
Stock market update: Nifty Pharma index advances 0.19%
The Nifty Pharma index closed 0.19 per cent up at 21684.4.
Underweight on US since January; overweight on Europe, China & India: Devina Mehra
Devina Mehra of First Global suggests remaining invested in Indian markets. They are underweight in the US since January. They favor Europe and maintain overweight positions in China and India. Recent rebalancing in India includes overweighting pharma and auto components since early 2024. FMCG and banks have seen increased weight. However, banks remain underweight despite recent additions.
Stock market update: Stocks that hit 52-week lows on NSE
Tata Steel, BEL, Sun Pharma, Infosys and Nestle India were among the top losers on NSE.
Stock market update: Nifty Pharma index falls 0.21% in an upbeat market
The Nifty Pharma index was trading 0.21 per cent down at 21599.7.
- Go To Page 1
Stock market update: Stocks that hit 52-week highs on NSE
Indef Manufacturing, Peria Karamalai Tea, Manaksia Coated, Reliance Home Fin and Federal Mogul, hit their fresh 52-week highs at 10:25AM.
Stock market update: Nifty Pharma index advances 1.28%
The Nifty Pharma index closed 1.28 per cent up at 21644.2.
Stock Radar: Strides Pharma breaks out from 7-month consolidation to hit fresh 52-week high; time to buy?
Strides Pharma Science stock shows positive movement. It broke a seven-month consolidation phase. Experts suggest a buy with a target of Rs 960 in 1-2 months. The stock demonstrated strong momentum, breaking resistance at Rs 760. Technical indicators support a bullish outlook. A stop loss is advised at Rs 750 for risk management. Market participation has increased.
Stock market update: Nifty Pharma index advances 1.03% in an upbeat market
The Nifty Pharma index was trading 1.03 per cent up at 21591.95.
Gland Pharma shares in focus after subsidiary Cenexi gets 11 observations from French regulator
Gland Pharma shares will be in focus after its subsidiary Cenexi received 11 observations from France’s ANSM following a GMP inspection at its Fontenay facility. The company clarified that operations remain unaffected and a CAPA plan has been accepted. Gland Pharma shares have risen 16% in a month, though the stock is still down 43% over three years.
Stocks in news: Vedanta, Gland Pharma, YES Bank, Power Grid, BEL
Markets experienced range-bound trading, closing slightly higher after Tuesday's dip. Vedanta Resources explores refinancing a $550 million credit facility, while Gland Pharma's Cenexi received observations from France's drug regulator. CA Basque Investments reduced its stake in YES Bank, and Power Grid acquired MEL Power Transmission Ltd. REC plans to raise funds, and BEL secured new orders worth Rs 537 crore.
Stock market update: Nifty Pharma index advances 0.08%
The Nifty Pharma index closed 0.08 per cent up at 21371.7.
Sensex rises! But these stocks fell 5% or more in Wednesday's session
In the Nifty pack, 32 stocks closed in the green, while 18 stocks ended in the red.
Sensex rises! These stocks gained over 10% on BSE
In the Nifty 50 index, 32 stocks ended in the green, while 18 stocks closed in the red in today's trade.
Sensex rises! But these stocks are down 5% or more on BSE
In the Nifty pack, 30 stocks were trading in the green, while 20 stocks were trading in the red.
Stock market update: Stocks that hit 52-week highs on NSE
Natural Capsule, Shree Global, GRSE, Pennar Ind and Interarch Building, hit their fresh 52-week highs at 11:24AM.
Stock market update: Nifty Pharma index advances 0.05% in an upbeat market
The Nifty Pharma index was trading 0.05 per cent up at 21364.0.
Stock market update: Stocks that hit 52-week lows on NSE
Trent, Sun Pharma, ONGC, NTPC and TCS were among the top losers on NSE.
Stock market update: Nifty Pharma index falls 0.06% in a weak market
The Nifty Pharma index was trading 0.06 per cent down at 21381.3.
Sensex falls! These stocks fell 5% or more in Monday's session
In the Nifty pack, 20 stocks closed in the green, while 30 stocks ended in the red.
Stock market update: Nifty Pharma index falls 0.22%
The Nifty Pharma index closed 0.22 per cent down at 21394.1.
Stock market update: Nifty Pharma index falls 0.42% in a weak market
The Nifty Pharma index was trading 0.42 per cent down at 21352.55.
Sensex falls! These stocks are down 5% or more on BSE
In the Nifty pack, 17 stocks were trading in the green, while 33 stocks were trading in the red.
Stock market update: Nifty Pharma index falls 0.68%
The Nifty Pharma index closed 0.68 per cent down at 21442.05.
Stock market update: Nifty Pharma index falls 0.64% in a weak market
The Nifty Pharma index was trading 0.64 per cent down at 21451.7.
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to 'Add' with a revised target price of Rs 1,330, citing potential decline in gRevlimid sales due to pricing competition and a temporary halt in Pen-G plant production. While Europe business shows promise with new launches and biosimilars, lowered FY26/27E EBITDA reflects anticipated lower sales from Eugia.
Macquarie sees potential upside in Indian pharma and CDMO stocks
Macquarie is optimistic about Indian pharma and CDMO companies, predicting significant upside potential due to recent market corrections and global supply chain shifts. Indian CDMOs are favored for their cost-effectiveness and regulatory compliance. However, the brokerage remains cautious about Indian hospitals, anticipating overcapacity and assigning 'underperform' ratings to Apollo Hospitals and Max Healthcare.
Load More
